TY - JOUR
T1 - Risk of thyroid as a first or second primary cancer. A population-based study in Italy, 1998–2012
AU - Crocetti, E.
AU - Mattioli, V.
AU - Buzzoni, C.
AU - Franceschi, S.
AU - Serraino, D.
AU - Vaccarella, S.
AU - Ferretti, S.
AU - Busco, S.
AU - Fedeli, U.
AU - Varvarà, M.
AU - Falcini, F.
AU - Zorzi, M.
AU - Carrozzi, G.
AU - Mazzucco, W.
AU - Gasparotti, C.
AU - Iacovacci, S.
AU - Toffolutti, F.
AU - Cavallo, R.
AU - Stracci, F.
AU - Russo, A.G.
AU - Caldarella, A.
AU - Rosso, S.
AU - Musolino, A.
AU - Mangone, L.
AU - Casella, C.
AU - Fusco, M.
AU - Tagliabue, G.
AU - Piras, D.
AU - Tumino, R.
AU - Guarda, L.
AU - Dinaro, Y.M.
AU - Piffer, S.
AU - Pinna, P.
AU - Mazzoleni, G.
AU - Fanetti, A.C.
AU - Dal Maso, L.
AU - group, for AIRTUM working
N1 - Export Date: 15 February 2022
PY - 2021/10
Y1 - 2021/10
N2 - Background: The number of patients living after a cancer diagnosis is increasing, especially after thyroid cancer (TC). This study aims at evaluating both the risk of a second primary cancer (SPC) in TC patients and the risk of TC as a SPC. Methods: We analyzed two population-based cohorts of individuals with TC or other neoplasms diagnosed between 1998 and 2012, in 28 Italian areas covered by population-based cancer registries. Standardized incidence ratios (SIRs) of SPC were stratified by sex, age, and time since first cancer. Results: A total of 38,535 TC patients and 1,329,624 patients with other primary cancers were included. The overall SIR was 1.16 (95% CI: 1.12–1.21) for SPC in TC patients, though no increase was shown for people with follicular (1.06) and medullary (0.95) TC. SPC with significantly increased SIRs was bone/soft tissue (2.0), breast (1.2), prostate (1.4), kidney (2.2), and hemolymphopoietic (1.4) cancers. The overall SIR for TC as a SPC was 1.49 (95% CI: 1.42–1.55), similar for all TC subtypes, and it was significantly increased for people diagnosed with head and neck (2.1), colon–rectum (1.4), lung (1.8), melanoma (2.0), bone/soft tissue (2.8), breast (1.3), corpus uteri (1.4), prostate (1.5), kidney (3.2), central nervous system (2.3), and hemolymphopoietic (1.8) cancers. Conclusions: The increased risk of TC after many other neoplasms and of few SPC after TC questions the best way to follow-up cancer patients, avoiding overdiagnosis and overtreatment for TC and, possibly, for other malignancies.
AB - Background: The number of patients living after a cancer diagnosis is increasing, especially after thyroid cancer (TC). This study aims at evaluating both the risk of a second primary cancer (SPC) in TC patients and the risk of TC as a SPC. Methods: We analyzed two population-based cohorts of individuals with TC or other neoplasms diagnosed between 1998 and 2012, in 28 Italian areas covered by population-based cancer registries. Standardized incidence ratios (SIRs) of SPC were stratified by sex, age, and time since first cancer. Results: A total of 38,535 TC patients and 1,329,624 patients with other primary cancers were included. The overall SIR was 1.16 (95% CI: 1.12–1.21) for SPC in TC patients, though no increase was shown for people with follicular (1.06) and medullary (0.95) TC. SPC with significantly increased SIRs was bone/soft tissue (2.0), breast (1.2), prostate (1.4), kidney (2.2), and hemolymphopoietic (1.4) cancers. The overall SIR for TC as a SPC was 1.49 (95% CI: 1.42–1.55), similar for all TC subtypes, and it was significantly increased for people diagnosed with head and neck (2.1), colon–rectum (1.4), lung (1.8), melanoma (2.0), bone/soft tissue (2.8), breast (1.3), corpus uteri (1.4), prostate (1.5), kidney (3.2), central nervous system (2.3), and hemolymphopoietic (1.8) cancers. Conclusions: The increased risk of TC after many other neoplasms and of few SPC after TC questions the best way to follow-up cancer patients, avoiding overdiagnosis and overtreatment for TC and, possibly, for other malignancies.
U2 - 10.1002/cam4.4193
DO - 10.1002/cam4.4193
M3 - Article
SN - 2045-7634
VL - 10
SP - 6855
EP - 6867
JO - Cancer Medicine
JF - Cancer Medicine
IS - 19
ER -